 Allogeneic, off-the-shelf CAR-T therapy with CD19CD7 dual-directed CAR shows promising early results in patients with rr B-ALL PALO ALTO, Calif. and SUZHOU, China , April 8, 2022 PRNewswire -- Gracell Biotechnologies Inc. Gracell or the Company, NASDAQ: GRCL, a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19CD7 dual-directed chimeric antigen receptor CAR T cell therapy for the treatment of relapsedrefractory B-cell acute lymphoblastic leukemia rr B-ALL. 